Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice

被引：0
|
作者：
Jadvar, Hossein [1 ,2 ]
Iravani, Amir [3 ]
Bodei, Lisa [4 ]
Calais, Jeremie [5 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Div Nucl Med, Los Angeles, CA 90007 USA
[2] Univ Southern Calif, Mol Imaging Ctr, Keck Sch Med, Dept Radiol, Los Angeles, CA 90007 USA
[3] Univ Washington, Dept Radiol, Div Nucl Med, Seattle, WA USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY USA
[5] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷 / 12期
关键词：
RESISTANT PROSTATE-CANCER; PROGRESSION-FREE SURVIVAL; PSMA PET/CT; 177LU-PSMA-617; MULTICENTER; SAFETY;
D O I：
10.2967/jnumed.124.268023
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：1851 / 1854
页数：4
相关论文
共 50 条
  • [31] The 177Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (03) : 343 - 343
  • [32] Value of Post-Therapy Quantitative SPECT for Monitoring Response to 177Lu-PSMA-617 Therapy
    Meyer, Catherine
    Yilmaz, Burcak
    Szidonya, Laszlo
    Winters, Celeste
    Mench, Anna
    Mallak, Nadine
    Mittra, Erik
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [33] Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC A Proof-of-Principle Application
    Bal, Chandrasekhar
    Yadav, Madhav Prasad
    Ballal, Sanjana
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (08) : E386 - E387
  • [34] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
    Qu, Gengcuo
    Hua, Qingchu
    Li, Hongmei
    Zhang, Yu
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
  • [35] 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
    von Eyben, Finn E.
    Kiljunen, Timo
    Joensuu, Timo
    Kairemo, Kalevi
    Uprimny, Christian
    Virgolini, Irene
    ONCOTARGET, 2017, 8 (39) : 66112 - 66116
  • [36] Whole-Body Dosimetry in Therapy of Metastatic Prostate Cancer with 177Lu-PSMA-617
    Happel, C.
    Voeller, L.
    Kranert, W. T.
    Groener, D.
    Bockisch, B.
    Mader, N.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S695 - S695
  • [37] 177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis
    Tonnelet, David
    Edet-Sanson, Agathe
    Augusto, Laetitia
    Cabourg, Marine
    Thureau, Sebastien
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (12) : E668 - E669
  • [38] Does Pre-Therapy PSA Influence 177Lu-PSMA-617 Treatment Outcomes?
    Fermawi, S.
    Buehner, T.
    Kalarn, S.
    Sabottke, C.
    Recio-Boiles, A.
    Savir-Baruch, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S363 - S363
  • [39] Fractionated 177Lu-PSMA-617 therapy with 101 GBq in a patient with metastatic prostate cancer
    Happel, C.
    Wichert, J.
    Kranert, W. T.
    Voeller, L.
    Bockisch, B.
    Groener, D.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S697 - S697
  • [40] First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
    Thomas J. W. Klein Nulent
    Robert J. J. van Es
    Stefan M. Willems
    Arthur. J. A. T. Braat
    Lot A. Devriese
    Remco de Bree
    Bart de Keizer
    EJNMMI Research, 11
12345